Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial.
- 2012-07
- RCT · n = 131
- Regulatory Toxicology and Pharmacology 63(2)
- M. Jones
- C. Martoni
- E. Di Pietro
- R. Simon
- S. Prakash
- PubMed: 22561556
- DOI: 10.1016/j.yrtph.2012.04.003
- High evidence
No clinically significant differences between the probiotic capsule and placebo capsule treated groups were detected in either the blood clinical chemistry or hematology results.
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- 2.9×10⁹ CFU twice daily